Laddar...
Comparison of extended to standard half-life recombinant factor VIII therapy in patients with hemophilia A on prophylactic therapy
Background: Hemophilia A is a genetic bleeding disorder caused by a deficiency in factor VIII (FVIII). FVIII maintains bleeding homeostasis within the body through its downstream effects on the intrinsic clotting cascade. The extent of the disease – mild, moderate or severe – depends on the amount o...
Sparad:
| I publikationen: | J Drug Assess |
|---|---|
| Huvudupphovsmän: | , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Taylor & Francis
2019
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6764360/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21556660.2019.1658327 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|